AU2016227618B2 - Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors - Google Patents

Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors Download PDF

Info

Publication number
AU2016227618B2
AU2016227618B2 AU2016227618A AU2016227618A AU2016227618B2 AU 2016227618 B2 AU2016227618 B2 AU 2016227618B2 AU 2016227618 A AU2016227618 A AU 2016227618A AU 2016227618 A AU2016227618 A AU 2016227618A AU 2016227618 B2 AU2016227618 B2 AU 2016227618B2
Authority
AU
Australia
Prior art keywords
compound
acid
alkyl
pharmaceutically
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016227618A
Other languages
English (en)
Other versions
AU2016227618A1 (en
Inventor
Conni Lauritzen
John Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuprozyme Therapeutics ApS
Original Assignee
Neuprozyme Therapeutics ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuprozyme Therapeutics ApS filed Critical Neuprozyme Therapeutics ApS
Publication of AU2016227618A1 publication Critical patent/AU2016227618A1/en
Assigned to Neuprozyme Therapeutics ApS reassignment Neuprozyme Therapeutics ApS Request for Assignment Assignors: PROZYMEX A/S
Application granted granted Critical
Publication of AU2016227618B2 publication Critical patent/AU2016227618B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
AU2016227618A 2015-03-05 2016-03-04 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors Active AU2016227618B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15157811 2015-03-05
EP15157811.9 2015-03-05
PCT/EP2016/054674 WO2016139351A1 (en) 2015-03-05 2016-03-04 Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors

Publications (2)

Publication Number Publication Date
AU2016227618A1 AU2016227618A1 (en) 2017-08-31
AU2016227618B2 true AU2016227618B2 (en) 2020-06-04

Family

ID=52648854

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016227618A Active AU2016227618B2 (en) 2015-03-05 2016-03-04 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors

Country Status (7)

Country Link
US (1) US10479781B2 (OSRAM)
EP (1) EP3265452B1 (OSRAM)
JP (1) JP6783426B2 (OSRAM)
AU (1) AU2016227618B2 (OSRAM)
CA (1) CA2978234C (OSRAM)
DK (1) DK3265452T3 (OSRAM)
WO (1) WO2016139351A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (OSRAM) 2014-01-24 2018-02-24
DK3265452T3 (en) 2015-03-05 2020-06-08 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
PL3758708T3 (pl) 2018-03-01 2025-03-31 Astrazeneca Ab Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
WO2022020245A1 (en) 2020-07-20 2022-01-27 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
WO2022232573A1 (en) * 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
IL321931A (en) 2023-01-06 2025-09-01 Insmed Inc New and reversible DPP1 inhibitors and their uses
WO2025162472A1 (en) * 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128324A1 (en) * 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2012119941A1 (en) * 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902181B2 (en) 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
WO2012130299A1 (en) * 2011-03-30 2012-10-04 Prozymex A/S Peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
KR102295740B1 (ko) 2013-03-14 2021-09-01 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드
IN2013MU02212A (OSRAM) 2013-07-01 2015-06-12 Mandar Agashe
JP6408008B2 (ja) * 2013-09-09 2018-10-17 プロザイメックス・アクティーゼルスカブＰｒｏＺｙｍｅｘ Ａ／Ｓ ジペプチジルペプチダーゼｉインヒビターとしてのペプチジルニトリル化合物
DK3265452T3 (en) 2015-03-05 2020-06-08 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128324A1 (en) * 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2012119941A1 (en) * 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Also Published As

Publication number Publication date
JP2018507223A (ja) 2018-03-15
AU2016227618A1 (en) 2017-08-31
US10479781B2 (en) 2019-11-19
CA2978234C (en) 2023-05-02
US20180044328A1 (en) 2018-02-15
CA2978234A1 (en) 2016-09-09
EP3265452B1 (en) 2020-03-04
DK3265452T3 (en) 2020-06-08
JP6783426B2 (ja) 2020-11-11
WO2016139351A1 (en) 2016-09-09
EP3265452A1 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
AU2016227618B2 (en) Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
CA2923484C (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2012119941A1 (en) Peptidyl nitrilcompounds as peptidase inhibitors
KR100416111B1 (ko) 아미딘 화합물
TW200922556A (en) Novel cathepsin C inhibitors and their use
WO2015032942A1 (en) N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
ES2332053T3 (es) Derivados 4-fenilpiperidina como inhibidores de renina.
ES2209244T3 (es) Inhibidores de las metaloproteasas de la matriz.
AU2010319927B2 (en) Alkynyl derivatives useful as DPP-1 inhibitors
WO2016139355A1 (en) N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
CZ20011506A3 (cs) Omega-amidy N-arylsulfonylaminokyselin, způsob jejich přípravy a léčivo, které je obsahuje
WO2012130299A1 (en) Peptidase inhibitors
CA2456096A1 (en) Novel amine derivative having human .beta.-tryptase inhibitory activity and medecine containing the same
US9187461B2 (en) Cathepsin C inhibitors
JP2024519091A (ja) 炎症性疾患またはがんを処置するためのオキソインドリン化合物
NZ718128B2 (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
JPH1171279A (ja) チアゾリジン類を有効成分として含有する狭心症予防剤又は治療剤
NZ614540B2 (en) Cathepsin c inhibitors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEUPROZYME THERAPEUTICS APS

Free format text: FORMER APPLICANT(S): PROZYMEX A/S

FGA Letters patent sealed or granted (standard patent)